Tumor-reactive T Cells
Tumor-reactive T Cells - Related Videos
07:20
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
0 Views •
Cited by 6 •
2011
An efficient protocol for the ex vivo expansion of tumor-reactive T cells from tumor-draining lymph nodes or other secondary lymphoid tissues of tumor-bearing hosts is described. This protocol selectively expands tumor-specific T cells for use in adoptive immunotherapy of breast cancer.
10:04
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
0 Views •
2025
This protocol describes the in vivo reprogramming of mouse cancer cells into type 1 dendritic-like cells within the tumor microenvironment through enforced expression of the transcription factors PU.1, IRF8, and BATF3.
04:28
Lung Tumor Cell Recruitment Assay
0 Views •
2019
This manuscript describes a method to quantify tumor cell accumulation in the lungs in an animal model of tumor metastasis.
09:08
Detecting Reactive Oxygen Species
0 Views •
2023
Reactive oxygen species are chemically active, oxygen-derived molecules capable of oxidizing other molecules. Because of their reactive nature, there are many deleterious effects associated with unchecked ROS production, including structural damage to DNA and other biological molecules. However, ROS can also be mediators of physiological signaling. There is accumulating evidence that ROS play significant roles in everything from activation of transcription factors to the mediation of...
02:12
Analyzing Neural Stem Cell Reactivation in Cultured Drosophila Brain Explants
0 Views •
2025
This video demonstrates a protocol to identify exogenous factors that initiate the reactivation of Drosophila brain neural stem cells from their quiescent state. Freshly hatched larvae are dissected to isolate their brains, which are then cultured in media with or without a test hormone to evaluate the hormone's potential to induce neural stem cell reactivation and proliferation.
FAQs
The T-cell receptor evaluates peptide–major histocompatibility complex combinations displayed by cells. Tumor-reactive cells respond when these presented antigen patterns are recognized, linking molecular specificity to selective immune activity against malignant targets. This recognition step provides a basis for studying how immune cells distinguish cancer from other cells and for assessing antigen-dependent antitumor responses.
After recognition, these cells can contribute to tumor control through several coordinated outputs. They may release cytotoxic molecules, produce cytokines, or recruit other immune cells to the target site. Measuring these different responses helps investigators distinguish simple antigen recognition from broader functional activity and characterize how strongly a T-cell population participates in antitumor immunity.
A detectable T-cell response does not by itself explain whether malignant cells will be eliminated. Cancer research therefore examines tumor-reactive cells together with tumor escape, asking how immune recognition and cancer persistence relate to one another. This comparison helps researchers interpret limitations in antitumor immunity and identify why immune activity may not translate into effective treatment responses.
Investigators commonly study these cells through three linked activities: isolation from a relevant sample, measurement of their recognition or functional responses, and expansion of selected populations. Together, these steps provide material for analyzing immune recognition and preparing cells for further investigation. The resulting data can also support comparisons of immune activity across tumors or treatment conditions.
Their antitumor activity provides a cellular basis for adoptive cell therapy approaches. Researchers study and expand responsive populations for strategies that include tumor-infiltrating lymphocyte treatments and engineered T-cell approaches. Comparing these formats helps cancer researchers investigate how naturally occurring or deliberately modified T-cell responses might be developed into treatments directed toward malignant targets.
The presence and activity of tumor-reactive T cells can provide information about a tumor’s immune landscape and about treatment response. Researchers use this information to evaluate whether antitumor immunity is detectable and how it changes in relation to therapy. Such measurements support efforts to improve personalized treatment by connecting immune features with patient-specific cancer research decisions.